How To Treat Dementia with Lewy bodies (DLB)?
Treatment of cognitive changesIn both DLB and PDD, the function of an important system of neurotransmitters (chemical messengers in the brain) known as the cholinergic system is reduced. ‘Cholinesterase inhibitors’ are a group of treatments that lower the breakdown of choline (so that there is more choline floating around in the brain), producing improvements in cognition. Rivastigmine1 and donepezil2, both cholinesterase inhibitors, show benefits in DLB in placebo controlled trials. A recent research study looked at evidence from a number of different trials and showed that donepezil and rivastigmine improve cognitive function, behavioural symptoms and activities of living and caregiver burden3 (see also4). The side effects of these treatments are similar, with nausea and vomiting most frequent. Memantine, a medication that works on the glutamatergic system (a different neurotransmitter system) has a positive overall impact but people taking memantine don’t show improvement on cognitive tests3;5.
Treatment of visual hallucinationsThe best approach to visual symptoms in DLB and PDD is to address reversible causes and to optimise the visual environment. Early treatment of cataracts and glaucoma is recommended. Medications that contribute to hallucinations or confusion should be stopped. Cholinesterase inhibitors, especially rivastigmine, improve hallucinations in some patients6. If this doesn’t improve things, doctors might then want to consider using antipsychotic medications.
Using antipsychotic treatments in Dementia with Lewy BodiesParticular care is needed when using antipsychotic medications in Dementia with Lewy Bodies due to the risk of severe antipsychotic sensitivity that can affect up to half of all patients. This causes muscle spasms, rigidity and tremor as well as confusion, and changes in heart rate and blood pressure7. General side effects include stiffness and rigidity,, involuntary movements and drowsiness. However, in some situations, antipsychotic treatment cannot be avoided, because the hallucinations are so distressing or the person is experiencing psychosis (really distorted reality) . ‘Clozapine’ is consistently the most effective medication for DLB-related hallucinations but requires blood monitoring due to the risk of a condition called ‘agranulocytosis’ (a particular change in the composition of blood). For this reason, ‘quetiapine’ is more frequently prescribed, although some tests in Parkinson’s related psychosis have not shown an effect in improving hallucinations8. Pimavanserin is a drug that works on another neurotransmitter, serotonin. It can be effective for hallucinations in Parkinson’s disease9 and may be a future treatment option for hallucinations in DLB.
Movement symptomsMovement symptoms can be an important cause of disability in DLB and may increase the likelihood of falls. L-DOPA (which are often labelled as Madopar and Sinemet on the packet) is the preferred treatment. L-DOPA is converted in the body to the neurotransmitter dopamine so increases dopamine levels. Dopamine agonists are a group of medications that mimic the effects of dopamine (but don’t actually increase dopamine levels like L-DOPA does). Experience in Parkinson’s disease suggests that L-DOPA is slightly less likely than dopamine agonists to cause visual hallucinations10. Doses should be carefully adjusted to avoid exacerbating confusion and dizziness on standing . Anticholinergics are another form of treatment for motor symptoms that reduce cholinergic activity and should be avoided as these may worsen confusion11.
Treatment of other symptoms
Want to keep
UCL (University College London) online course,
The Many Faces of Dementia
OverallYou can see from this article that working out the best medicine, or set of medicines, for someone with DLB or PPD is not easy. Some medicines that are useful in other forms of dementia, are not useful here. Some medicines improve some symptoms (e.g. slowness and stiffness) but might make others worse (e.g. hallucinations). Doctors will often try starting someone on a low dose of a medicine and gradually building it up to make sure that it’s working, without unacceptable side effects. You can also see how it is really important to be as certain as possible about the diagnosis before you give someone a medicine, because what works for one sort of dementia can actually make things worse in others.
(1) McKeith I, Del ST, Spano P, Emre M, Wesnes K, Anand R et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000; 356(9247):2031-2036. (2) Mori E, Ikeda M, Kosaka K. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Ann Neurol 2012; 72(1):41-52. (3) Wang HF, Yu JT, Tang SW, Jiang T, Tan CC, Meng XF et al. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry 2015; 86(2):135-143. (4) Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev 2012; 3:CD006504. (5) Matsunaga S, Kishi T, Iwata N. Memantine for Lewy body disorders: systematic review and meta-analysis. Am J Geriatr Psychiatry 2015; 23(4):373-383. (6) Aarsland D, Mosimann UP, McKeith IG. Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol 2004; 17(3):164-171. (7) McKeith I, Fairbairn A, Perry R, Thompson P, Perry E. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 1992; 305(6855):673-678. (8) Ferreira JJ, Katzenschlager R, Bloem BR, Bonuccelli U, Burn D, Deuschl G et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. Eur J Neurol 2013; 20(1):5-15. (9) Meltzer HY, Mills R, Revell S, Williams H, Johnson A, Bahr D et al. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis. Neuropsychopharmacology 2010; 35(4):881-892. (10) Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 2000; 342(20):1484-1491. (11) McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65(12):1863-1872. (12) Ballard C, Kahn Z, Corbett A. Treatment of dementia with Lewy bodies and Parkinson's disease dementia. Drugs Aging 2011; 28(10):769-777.
The Many Faces of Dementia
Our purpose is to transform access to education.
We offer a diverse selection of courses from leading universities and cultural institutions from around the world. These are delivered one step at a time, and are accessible on mobile, tablet and desktop, so you can fit learning around your life.
We believe learning should be an enjoyable, social experience, so our courses offer the opportunity to discuss what you’re learning with others as you go, helping you make fresh discoveries and form new ideas.
You can unlock new opportunities with unlimited access to hundreds of online short courses for a year by subscribing to our Unlimited package. Build your knowledge with top universities and organisations.